keyword
Keywords Intravenous Iron in non dialys...

Intravenous Iron in non dialysis patients

https://read.qxmd.com/read/34830468/hypoxia-inducible-factor-stabilizers-in-end-stage-kidney-disease-can-the-promise-be-kept
#21
REVIEW
Giuseppina Crugliano, Raffaele Serra, Nicola Ielapi, Yuri Battaglia, Giuseppe Coppolino, Davide Bolignano, Umberto Marcello Bracale, Antonio Pisani, Teresa Faga, Ashour Michael, Michele Provenzano, Michele Andreucci
Anemia is a common complication of chronic kidney disease (CKD). The prevalence of anemia in CKD strongly increases as the estimated Glomerular Filtration Rate (eGFR) decreases. The pathophysiology of anemia in CKD is complex. The main causes are erythropoietin (EPO) deficiency and functional iron deficiency (FID). The administration of injectable preparations of recombinant erythropoiesis-stimulating agents (ESAs), especially epoetin and darbepoetin, coupled with oral or intravenous(iv) iron supplementation, is the current treatment for anemia in CKD for both dialysis and non-dialysis patients...
November 22, 2021: International Journal of Molecular Sciences
https://read.qxmd.com/read/34510284/preliminary-experience-on-the-use-of-sucrosomial-iron-in-hemodialysis-focus-on-safety-hemoglobin-maintenance-and-oxidative-stress
#22
JOURNAL ARTICLE
Francesco Reggiani, Graziano Colombo, Emanuela Astori, Lucia Landoni, Silvia Finazzi, Aldo Milzani, Claudio Angelini, Isabella Dalle-Donne, David Cucchiari
PURPOSE: Iron is usually administered in hemodialysis patients by parenteral route, as oral absorption is poor due to high hepcidin levels. However, administrations of intravenous iron and iron overload are associated with high oxidative stress and systemic inflammation that can affect patient survival. With this study, we evaluated an alternative type of oral iron for the treatment of anemia in hemodialysis patients. The formulation consists in ferric pyrophosphate covered by phospholipids plus sucrose ester of fatty acid matrix, named sucrosomial iron, whose absorption is not influenced by hepcidin...
May 2022: International Urology and Nephrology
https://read.qxmd.com/read/34259226/intravenous-iron-therapy-in-a-rural-hospital-a-retrospective-chart-review
#23
JOURNAL ARTICLE
Ribal Kattini, Jenna Poirier, Lauren Minty, Danielle LaJuenesse, Len Kelly, Sharen Madden, Robert Minty, Sydney Larsen, Ruben Hummelen
Introduction: Intravenous iron infusion therapy is commonly delivered in rural hospitals, but there are no common guidelines for dosing or choice of agent. The objective of the study was to understand present practice and alternate therapies and develop practical recommendations for small hospital use. Methods: This was a retrospective chart review of all non-dialysis patients aged 15 years or older who received iron replacement therapy at Sioux Lookout Meno Ya Win Health Centre from May 2013 to May 2019 and a literature review of available iron preparations...
July 2021: Canadian Journal of Rural Medicine
https://read.qxmd.com/read/34162484/safety-and-efficacy-of-intravenous-ferric-derisomaltose-compared-to-iron-sucrose-for-iron-deficiency-anemia-in-patients-with-chronic-kidney-disease-with-and-without-heart-failure
#24
RANDOMIZED CONTROLLED TRIAL
Andrew P Ambrosy, Stephan von Haehling, Paul R Kalra, Emma Court, Sunil Bhandari, Theresa McDonagh, John G F Cleland
Ferric derisomaltose (FDI) is an intravenous (IV) high-dose iron formulation approved in the US for the treatment of iron deficiency anemia in adults who are intolerant of/have had an unsatisfactory response to oral iron, or who have non-dialysis-dependent chronic kidney disease (NDD-CKD). FERWON-NEPHRO was a randomized, open-label, multicenter clinical trial evaluating the safety and efficacy of a single infusion of FDI 1,000 mg versus up to 5 doses of iron sucrose (IS) 200 mg (recommended cumulative dose, 1,000 mg) over 8 weeks in patients with NDD-CKD and iron deficiency anemia...
August 1, 2021: American Journal of Cardiology
https://read.qxmd.com/read/34077510/roxadustat-for-the-treatment-of-anaemia-in-chronic-kidney-disease-patients-not-on-dialysis-a-phase-3-randomized-open-label-active-controlled-study-dolomites
#25
RANDOMIZED CONTROLLED TRIAL
Jonathan Barratt, Branislav Andric, Avtandil Tataradze, Michael Schömig, Michael Reusch, Udaya Valluri, Christophe Mariat
BACKGROUND: Roxadustat, an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor, is being evaluated for treatment of anaemia of chronic kidney disease (CKD). METHODS: This randomized, open-label, active-controlled Phase 3 study compared roxadustat versus darbepoetin alfa (DA) in non-dialysis-dependent (NDD) CKD patients with anaemia for ≤104 weeks. Doses were titrated to correct and maintain haemoglobin (Hb) within 10.0-12.0 g/dL. The primary endpoint was Hb response in the full analysis set, defined as Hb ≥11...
August 27, 2021: Nephrology, Dialysis, Transplantation
https://read.qxmd.com/read/34053886/iron-replacement-therapy-in-the-management-of-anaemia-in-non-dialysis-chronic-kidney-disease-patients-perspective-of-the-spanish-nephrology-society-anaemia-group
#26
REVIEW
Aleix Cases, Maria Jesús Puchades, Patricia de Sequera, Borja Quiroga, Leyre Martin-Rodriguez, José Luis Gorriz, José Portolés
This work presents an update on the management of iron deficiency in patients with chronic kidney disease (CKD), either with or without anaemia. A review is made of the recommendations of the guidelines for the treatment of iron deficiency in CKD. It also presents new studies on iron deficiency in patients with CKD, as well as new findings about iron therapy and its impact on clinical outcomes. Anaemia is a common complication of CRF, and is associated with a decrease in the quality of life of the patients, as well as an increase in morbidity and mortality...
March 2021: Nefrología: Publicación Oficial de la Sociedad Española Nefrologia
https://read.qxmd.com/read/33811227/ferric-carboxymaltose-vs-ferrous-sulfate-for-the-treatment-of-anemia-in-advanced-chronic-kidney-disease-an-observational-retrospective-study-and-cost-analysis
#27
COMPARATIVE STUDY
Luigi Cirillo, Chiara Somma, Marco Allinovi, Alfredo Bagalà, Giuseppe Ferro, Elio Di Marcantonio, Stefania Bellelli, Lorenzo Antonio Dallari, Piercarlo Ballo, Pietro Claudio Dattolo
In non-dialysis-dependent chronic kidney disease (NDD-CKD), erythropoiesis-stimulating agents (ESAs) and iron supplementation are essential for anemia management. Ferric carboxymaltose (FCM) is a relatively novel intravenous iron formulation used in different clinical settings, although scarce data exist in NDD-CKD patients. Primary objective of this study was to retrospectively evaluate the efficacy of FCM compared with oral ferrous sulfate for the treatment of iron-deficiency anemia in a cohort of NDD-CKD patients, considering also the treatment costs...
April 2, 2021: Scientific Reports
https://read.qxmd.com/read/33806864/ferric-carboxymatose-in-non-hemodialysis-ckd-patients-a-longitudinal-cohort-study
#28
JOURNAL ARTICLE
Roberto Minutolo, Patrizia Berto, Maria Elena Liberti, Nicola Peruzzu, Silvio Borrelli, Antonella Netti, Carlo Garofalo, Giuseppe Conte, Luca De Nicola, Lucia Del Vecchio, Francesco Locatelli
No information is available on the efficacy of ferric carboxymaltose (FCM) in real-world CKD patients outside the hemodialysis setting. We prospectively followed 59 non-hemodialysis CKD patients with iron deficient anemia (IDA: hemoglobin <12.0/<13.5 g/dL in women/men and TSAT < 20% and/or ferritin < 100 ng/mL) who were intolerant or non-responders to oral iron. Patients received ferric carboxymaltose (FCM) (single dose of 500 mg) followed by additional doses if iron deficiency persisted. We evaluated efficacy of FCM in terms of increase of hemoglobin, ferritin, and TSAT levels...
March 23, 2021: Journal of Clinical Medicine
https://read.qxmd.com/read/33784968/a-multicentre-prospective-double-blinded-randomised-controlled-trial-of-intravenous-iron-ferric-derisomaltose-fdi-in-iron-deficient-but-not-anaemic-patients-with-chronic-kidney-disease-on-functional-status
#29
RANDOMIZED CONTROLLED TRIAL
S Bhandari, V Allgar, A Lamplugh, I Macdougall, P A Kalra
BACKGROUND: Iron deficiency (ID) is common in patients with chronic kidney disease (CKD). Intravenous (IV) iron in heart failure leads to improvement in exercise capacity and improvement in quality-of-life measurements; however, data in patients with CKD are lacking. METHODS: The Iron and the Heart Study was a prospective double blinded randomised study in non-anaemic CKD stages 3b-5 patients with ID which investigated whether 1000 mg of IV iron (ferric derisomaltose (FDI)) could improve exercise capacity in comparison to placebo measured at 1 and 3 months post infusion...
March 30, 2021: BMC Nephrology
https://read.qxmd.com/read/33745264/the-comparative-effects-of-intravenous-iron-on-oxidative-stress-and-inflammation-in-patients-with-chronic-kidney-disease-and-iron-deficiency-a-randomized-controlled-pilot-study
#30
JOURNAL ARTICLE
Xenophon Kassianides, Andrew Gordon, Roger Sturmey, Sunil Bhandari
Background: Concerns exist regarding the pro-oxidant and inflammatory potential of intravenous (IV) iron due to labile plasma iron (LPI) generation. This IRON-CKD trial compared the effects of different IV irons on oxidative stress and inflammation. Methods: In this randomized open-label explorative single-center study in the United Kingdom, non-dialysis-dependent chronic kidney disease (CKD) patients with iron deficiency were randomized (1:1:1:1) to receive a single infusion of 200 mg iron dextran, or 200 mg iron sucrose (IS), or 200 mg or 1,000 mg ferric derisomaltose (FDI) and were followed up for 3 months...
March 22, 2021: Kidney Research and Clinical Practice
https://read.qxmd.com/read/33744933/study-design-and-baseline-characteristics-of-patients-on-dialysis-in-the-ascend-d-trial
#31
RANDOMIZED CONTROLLED TRIAL
Ajay K Singh, Allison Blackorby, Borut Cizman, Kevin Carroll, Alexander R Cobitz, Rich Davies, Vivekanand Jha, Kirsten L Johansen, Renato D Lopes, Lata Kler, Iain C Macdougall, John J V McMurray, Amy M Meadowcroft, Gregorio T Obrador, Vlado Perkovic, Scott Solomon, Christoph Wanner, Sushrut S Waikar, David C Wheeler, Andrzej Wiecek
BACKGROUND: The Anemia Studies in chronic kidney disease (CKD): Erythropoiesis via a Novel prolyl hydroxylase inhibitor Daprodustat-Dialysis (ASCEND-D) trial will test the hypothesis that daprodustat is noninferior to comparator epoetin alfa or darbepoetin alfa for two co-primary endpoints: hemoglobin (Hb) efficacy and cardiovascular (CV) safety. METHODS: We report the trial design, key demographic, clinical and laboratory findings, and baseline therapies of 2964 patients randomized in the open-label (sponsor-blinded) active-controlled, parallel-group, randomized ASCEND-D clinical trial...
April 25, 2022: Nephrology, Dialysis, Transplantation
https://read.qxmd.com/read/33675476/using-iron-based-phosphate-binders-in-phosphate-reduction-and-anemia-improvement-in-patients-receiving-dialysis-a-meta-analysis-of-randomized-controlled-trials
#32
JOURNAL ARTICLE
Yan Zhu, Jinlan Rao, Xueling Liao, Jihong Ou, Wei Li, Chao Xue
PURPOSE: A study was conducted to determine whether iron-based phosphate binders (IBPBs) need to be preferred for hyperphosphatemia and anemia management in patients on dialysis. METHODS: For this meta-analysis, we searched PubMed, Embase, and Cochrane Central Register of Controlled Trials for randomized controlled trials that evaluated the efficacy and safety of IBPBs in decreasing phosphate and correcting anemia in dialysis patients. RESULTS: Nineteen trials comprising 4719 participants were included...
March 6, 2021: International Urology and Nephrology
https://read.qxmd.com/read/33670704/esa-iron-therapy-and-new-drugs-are-there-new-perspectives-in-the-treatment-of-anaemia
#33
REVIEW
Lucia Del Vecchio, Roberto Minutolo
Anemia is a well-known consequence of chronic kidney disease (CKD); it is mainly due to a relative insufficiency of erythropoietin synthesis by the failing kidneys. Over the years, the combination of erythropoiesis stimulating agents (ESA) and iron has become the standard of care of anemia. All ESAs effectively increase hemoglobin (Hb) levels in a substantial percentage of patients. However, in the last decade, their use has been surrounded by safety issues in increased cardiovascular risk, especially when used at high doses in inflamed and hyporesponsive patients...
February 18, 2021: Journal of Clinical Medicine
https://read.qxmd.com/read/33564416/effectiveness-and-safety-of-ferric-carboxymaltose-therapy-in-peritoneal-dialysis-patients-an-observational-study
#34
JOURNAL ARTICLE
Jose Portolés-Pérez, Beatriz Durá-Gúrpide, José Luis Merino-Rivas, Leyre Martín-Rodriguez, Covadonga Hevia-Ojanguren, Victor Burguera-Vion, Claudia Yuste-Lozano, Luisa Sánchez-García, Jose Ramon Rodriguez-Palomares, Vicente Paraiso
Background: The efficacy of intravenous (IV) ferric carboxymaltose (FCM) has been demonstrated in haemodialysis and non-dialysis studies, but evidence is lacking in patients undergoing peritoneal dialysis (PD). Methods: This multicentre, retrospective study evaluated the effectiveness and safety of FCM in patients on PD over 12 months. We retrospectively reviewed the electronic medical records of PD patients who initiated FCM treatment between 2014 and 2017 across seven Spanish centres...
January 2021: Clinical Kidney Journal
https://read.qxmd.com/read/33516607/iron-replacement-therapy-in-the-management-of-anaemia-in-non-dialysis-chronic-renal-failure-patients-perspective-of-the-spanish-nephrology-society-anaemia-group
#35
REVIEW
Aleix Cases, Maria Jesús Puchades, Patricia de Sequera, Borja Quiroga, Leyre Martin-Rodriguez, José Luis Gorriz, José Portolés
This work presents an update on the management of iron deficiency in patients with chronic renal failure (CRF), either with or without anaemia. A review is made of the recommendations of the guidelines for the treatment of iron deficiency in CRF. It also presents new studies on iron deficiency in patients with CRF, as well as new findings about iron deficiency and its impact on clinical outcomes. Anaemia is a common complication of CRF, and is associated with a decrease in the quality of life of the patients, as well as an increase in morbidity and mortality...
March 2021: Nefrología
https://read.qxmd.com/read/33469061/a-real-world-longitudinal-study-of-anemia-management-in-non-dialysis-dependent-chronic-kidney-disease-patients-a-multinational-analysis-of-ckdopps
#36
JOURNAL ARTICLE
Marcelo Barreto Lopes, Charlotte Tu, Jarcy Zee, Murilo Guedes, Ronald L Pisoni, Bruce M Robinson, Bryce Foote, Katarina Hedman, Glen James, Antonio Alberto Lopes, Ziad Massy, Helmut Reichel, James Sloand, Sandra Waechter, Michelle M Y Wong, Roberto Pecoits-Filho
Previously lacking in the literature, we describe longitudinal patterns of anemia prescriptions for non-dialysis-dependent chronic kidney disease (NDD-CKD) patients under nephrologist care. We analyzed data from 2818 Stage 3-5 NDD-CKD patients from Brazil, Germany, and the US, naïve to anemia medications (oral iron, intravenous [IV] iron, or erythropoiesis stimulating agent [ESA]) at enrollment in the CKDopps. We report the cumulative incidence function (CIF) of medication initiation stratified by baseline characteristics...
January 19, 2021: Scientific Reports
https://read.qxmd.com/read/33462793/the-effect-of-iron-supplementation-on-fgf23-in-chronic-kidney-disease-patients-a-systematic-review-and-time-response-meta-analysis
#37
REVIEW
Ahmed Abu-Zaid, Duha Magzoub, Mohammad Abdulrahman Aldehami, Abdulrahman Adel Behiry, Akshaya Srikanth Bhagavathula, Raouf Hajji
Fibroblast growth factor 23 (FGF23) gene is found to be responsible for autosomal dominant hypophosphatemic rickets, and is highly expressed in chronic kidney disease (CKD) and end-stage renal disease patients with iron deficiency anemia (IDA). We evaluated the efficacy of different iron treatments on FGF23 levels in dialysis-dependent and non-dialysis-dependent CKD patients with IDA. We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing different types of iron treatment versus placebo in CKD patients up to May 2020...
December 2021: Biological Trace Element Research
https://read.qxmd.com/read/33461526/the-association-of-erythropoietin-stimulating-agents-and-increased-risk-for-av-fistula-dysfunction-in-hemodialysis-patients-a-retrospective-analysis
#38
JOURNAL ARTICLE
Anna Wärme, Henrik Hadimeri, Salmir Nasic, Bernd Stegmayr
BACKGROUND: Patients in maintenance hemodialysis (HD) need a patent vascular access for optimal treatment. The recommended first choice is a native arteriovenous fistula (AVF). Complications of AVF are frequent and include thrombosis, stenosis and infections leading to worsening of dialysis efficacy. Some known risk factors are age, gender and the presence of diabetes mellitus. The aim was to investigate if further risk variables are associated with dysfunctional AVF. METHODS: This retrospective observational study included 153 chronic HD patients (Cases) referred to a total of 473 radiological investigations due to clinically suspected complications of their native AVF...
January 18, 2021: BMC Nephrology
https://read.qxmd.com/read/33302891/nimo-ckd-uk-a-real-world-observational-study-of-iron-isomaltoside-in-patients-with-iron-deficiency-anaemia-and-chronic-kidney-disease
#39
JOURNAL ARTICLE
Philip A Kalra, Sunil Bhandari, Michael Spyridon, Rachel Davison, Sarah Lawman, Ashraf Mikhail, David Reaich, Nick Pritchard, Kieran McCafferty, Jason Moore
BACKGROUND: Intravenous iron is often used to treat iron deficiency anaemia in non-dialysis chronic kidney disease (ND-CKD), but the optimal dosing regimen remains unclear. We evaluated the impact of high- versus low-dose intravenous iron isomaltoside on the probability of retreatment with intravenous iron in iron-deficient ND-CKD patients. METHODS: This real-world, prospective, observational study collected data from 256 ND-CKD patients treated for anaemia in the UK...
December 10, 2020: BMC Nephrology
https://read.qxmd.com/read/32823844/the-role-of-iron-and-erythropoietin-in-the-association-of-fibroblast-growth-factor-23-with-anemia-in-chronic-kidney-disease-in-humans
#40
JOURNAL ARTICLE
Bernhard Bielesz, Thomas Reiter, Fabian Peter Hammerle, Wolfgang Winnicki, Marija Bojic, Andreas Gleiss, Heidi Kieweg, Franz Ratzinger, Gere Sunder-Plassmann, Rodrig Marculescu
Anemia in chronic kidney disease (CKD) is an almost universal complication of this condition. Fibroblast growth factor 23 (FGF23), a key-player in mineral metabolism, is reportedly associated with anemia and hemoglobin levels in non-dialysis CKD patients. Here, we sought to further characterize this association while taking into account the biologically active, intact fraction of FGF23, iron metabolism, and erythropoietin (EPO). Hemoglobin, EPO, iron, and mineral metabolism parameters, including both intact and c-terminal-FGF23 (iFGF23 and cFGF23, respectively) were measured cross-sectionally in 225 non-dialysis CKD patients (stage 1-5, median eGFR: 30 mL/min...
August 14, 2020: Journal of Clinical Medicine
keyword
keyword
83089
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.